Simona Re
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simona Re has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrea E. Gini
Museo di Storia Naturale, https://dx.doi.org/9310Università di Pisa, Via Roma 79, Calci, 56011, Italy
2 shared publications - Angelo Facchini
IMT School for Advanced Studies Lucca, Lucca, Italy
2 shared publications - Natascia Brondino
Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy
2 shared publications Niccolò Lanati
Department of Public Health, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy
2 shared publications- Pierluigi Politi
Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy
2 shared publications Anna Verna
Department of Brain and Behavioral Sciences
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in Data in Brief
- Vol. 68
Construction of a potential ecological network based on public datasets: a case study in Tuscany
- 22 July 2026
- Published by Elsevier in Data in Brief
- Vol. 68
Open AccessConstruction of a potential ecological network based on public datasets: a case study in Tuscany
- Open Access
- 17 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
A network simplification approach to ease topological studies about the food-web architecture
Food webs studies are intrinsically complex and time-consuming. Network data about trophic interaction across different large locations and ecosystems are scarce in comparison with general ecological data, especially if we consider terrestrial habitats. Here we present a complex network strategy to ease the gathering of the information by simplifying the collection of data with a taxonomic key. We test how well the topology of three different food webs retain their structure at the resolution of the nodes across distinct levels of simplification, and we estimate how community detection could be impacted by this strategy. The first level of simplification retains most of the general topological indices; betweenness and trophic levels seem to be consistent and robust even at the higher levels of simplification. This result suggests that generalisation and standardisation, as a good practice in food webs science, could benefit the community, both increasing the amount of open data available and the comparison among them, thus providing support especially for scientists that are new in this field and for exploratory analysis.
- 17 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Open AccessA network simplification approach to ease topological studies about the food-web architecture
Food webs studies are intrinsically complex and time-consuming. Network data about trophic interaction across different large locations and ecosystems are scarce in comparison with general ecological data, especially if we consider terrestrial habitats. Here we present a complex network strategy to ease the gathering of the information by simplifying the collection of data with a taxonomic key. We test how well the topology of three different food webs retain their structure at the resolution of the nodes across distinct levels of simplification, and we estimate how community detection could be impacted by this strategy. The first level of simplification retains most of the general topological indices; betweenness and trophic levels seem to be consistent and robust even at the higher levels of simplification. This result suggests that generalisation and standardisation, as a good practice in food webs science, could benefit the community, both increasing the amount of open data available and the comparison among them, thus providing support especially for scientists that are new in this field and for exploratory analysis.
- Open Access
- 22 January 2014
- Published by Wiley in The Scientific World Journal
- Vol. 2014, 1-6
Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies
Dementia is a leading health problem worldwide, with Alzheimer’s disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Severalin vitroandin vivostudies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy betweenin vitroandin vivofindings and human trials, such as low bioavailability and poor study design.
- 22 January 2014
- Published by Wiley in The Scientific World Journal
- Vol. 2014, 1-6
Open AccessCurcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies
Dementia is a leading health problem worldwide, with Alzheimer’s disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Severalin vitroandin vivostudies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy betweenin vitroandin vivofindings and human trials, such as low bioavailability and poor study design.
- Open Access
- 28 May 2013
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2013, 1-11
A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine
Ginkgo biloba(Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.
- 28 May 2013
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2013, 1-11
Open AccessA Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine
Ginkgo biloba(Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.